Subcuticular Absorbable Staples Versus Conventional Skin Closure in Women Undergoing Cesarean Delivery

Sponsor
The University of Texas Medical Branch, Galveston (Other)
Overall Status
Recruiting
CT.gov ID
NCT05112640
Collaborator
Cooper Companies (Industry)
316
1
2
28.5
11.1

Study Details

Study Description

Brief Summary

Despite the high numbers of cesareans being performed, scientific evidence behind which surgical techniques are best remains uncertain. Our objective is to determine if subcuticular absorbable staples improve operative time and wound cosmetics.

Condition or Disease Intervention/Treatment Phase
  • Device: INSORB: subcuticular stapling device
  • Device: Subcuticular monocryl suture manufactured by Ethicon
N/A

Detailed Description

This will be an open-label randomized controlled clinical trial. Women undergoing cesarean delivery will be randomized to have either standard wound closure with Monocryl suture or absorbable subcuticular staples placed by INSORB skin stapling device. The INSORB under the skin stapling device is FDA approved but not currently used as standard of care at UTMB. We will exclude women with intraamniotic infection, immunosuppression, active skin infection, those unlikely to be followed-up after delivery, or unable to provide consent.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
316 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Subjects who agree to participate in the study will be randomized to one of the two groups below in a 1/1 allocationSubjects who agree to participate in the study will be randomized to one of the two groups below in a 1/1 allocation
Masking:
Single (Outcomes Assessor)
Masking Description:
Reviewers of wound cosmetics during the post operative time will be blind to the intervention. However, surgeon at the time skin closure and patient will not be blinded to the intervention.
Primary Purpose:
Other
Official Title:
Subcuticular Absorbable Staples Versus Conventional Skin Closure in Women Undergoing Cesarean Delivery: A Randomized Control Trial
Actual Study Start Date :
Nov 16, 2021
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Mar 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Suture wound closure

Absorbable sutures for closure of cesarean skin incision using Monocryl manufactured by Ethicon.

Device: Subcuticular monocryl suture manufactured by Ethicon
Under the skin suture placed by hand

Experimental: Absorbable staple wound closure

Staples will be applied as per the manufacturer's instructions intraoperatively using INSORB device manufactured by Cooper Surgical.

Device: INSORB: subcuticular stapling device
Under the skin stapling device that delivers absorbable staples

Outcome Measures

Primary Outcome Measures

  1. Operating time [Start of surgery through end of skin closure]

    Total time for the procedure

Secondary Outcome Measures

  1. Wound cosmesis [Time of surgery through six weeks post partum]

    A digital photograph of the incision will be obtained on wound check visit POD 5-10 days and 4-6 weeks postoperative. Each photograph will be evaluated according to objective criteria (width, elevation, color, marks, and general appearance) by independent blinded research staff

  2. Composite wound complication [Time of surgery through six weeks post partum]

    Hematoma, seroma, dehiscence, breakdown of wound, wound infection, endometritis, sepsis, post part fevers

  3. Post operative pain [Time of surgery through six weeks post partum]

    Pain scale ranging from 0-10 on postoperative days 1 to 3 as well as at wound check visit recorded by nursing staff

  4. Adverse events [Time of surgery through six weeks post partum]

    Allergic reactions: anaphylaxis, angioedema, skin rashes, including Stevens Johnson and Toxic Epidermal Necrolysis

  5. Use of resources [Time of surgery through six weeks post partum]

    Hospital stay, postpartum clinic or emergency room visit within 30 days of delivery, need for imaging or other invasive procedures

  6. Patient satisfaction [Time of surgery through six weeks post partum]

    Questionnaire POD 2-3 (before discharge) and at wound check visit

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 18-50 years of age

  • Women ≥ 24 weeks viable gestation

  • Will be undergoing cesarean delivery

Exclusion Criteria:
  • Patient unwilling or unable to provide consent.

  • No or very limited prenatal care or a non-resident patient who is unlikely to follow-up after delivery.

  • Immunosuppressed subjects: i.e., taking systemic immunosuppressant or steroids (e.g. transplant subjects; not including steroids for lung maturity), HIV with CD4 <200, or other

  • Decision not to have skin closure (e.g. secondary wound closure, mesh closure)

  • Current skin infection

  • Coagulopathy

  • High likelihood of additional surgical procedure beyond cesarean (e.g. scheduled hysterectomy, tubal ligation, bowel or adnexal surgery)

  • Incarcerated individuals

  • Intraamniotic infection

  • Subjects participating on other treatment trials or studies that would interfere with the current study's primary outcome.

Contacts and Locations

Locations

Site City State Country Postal Code
1 John Sealy Hospital at University of Texas Medical Branch Galveston Texas United States 77555

Sponsors and Collaborators

  • The University of Texas Medical Branch, Galveston
  • Cooper Companies

Investigators

  • Principal Investigator: George Saade, MD, Division Director/Co-PI

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Goldman, Brett R, Fellow Physician, The University of Texas Medical Branch, Galveston
ClinicalTrials.gov Identifier:
NCT05112640
Other Study ID Numbers:
  • 21-0045
First Posted:
Nov 9, 2021
Last Update Posted:
Nov 26, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes

Study Results

No Results Posted as of Nov 26, 2021